Hydroxycobalamin
Contents
Description
Hydroxycobalamin is a precursor of vitamin B12 with higher tissue retention than cyanocobalamin. It is used in the treatment of methylmalonic acidemia and combined malonic and methylmalonic acidemia by serving as a cofactor for methylmalonyl-CoA mutase. The drug helps convert methylmalonyl-CoA to succinyl-CoA, reducing toxic metabolite accumulation.
Indications & Therapeutic Use
methylmalonic acidemia, combined malonic and methylmalonic acidemia, cyanide poisoning, vitamin B12 deficiency
Linked Diseases:
Global Availability (8 countries)
| Country | Access Route | Regulatory Pathway | Lead Time | Status |
|---|---|---|---|---|
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — | |
| — | — | — | — |
Buy / Source Hydroxycobalamin — GNH India
40 matching products available through GNH India. Select a product to view details and request a quote on the GNH India website.
Products and ordering are fulfilled by GNH India. You will be redirected to www.gnhindia.com.
Available Through
This drug is available for procurement through the following fulfilment partner.
| Generic Name | hydroxycobalamin |
| Brands | 1 brand available |
| Active Ingredient | hydroxocobalamin |
| Drug Class | methylmalonic acidemia |
| Manufacturer | Recordati Rare Diseases |
| Dosage Forms | intramuscular injection 1000 mcg/mL, intravenous infusion 2.5 g/vial |
| Medical Code | V03AB33 |
| Orphan Status | Yes — Orphan Drug |
| Cold Chain | Not Required |
| Lead Time | 14 days |
| Reg. Status | FDA Approved, EMA Approved |
| Countries | 8 countries |